![Fig. 3. Immunotherapy of A31- or BCL1-bearing mice with BsAb directed against huCD64 on the effector cells and Id on the tumors. / Groups of 5 huCD64+ age-matched mice received 2 μg/d murine G-CSF subcutaneously, 4 days before tumor inoculation, and throughout the course of therapy (10 days in total). Mice were inoculated with either 105 (BCL1) or 2 × 105 (A31) tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of 5 μg BsAb intraperitoneally on days 1 to 5 (50 μg/mouse in total). (This treatment schedule is shown in the inset.) Treatment was as indicated: PBS (●), anti-huCD64 F(ab')2 (⋄), anti-Id F(ab')2 (■), a mixture of anti-Id and anti-huCD64 F(ab')2 (♦), [huCD64 × Id] (○). Symbol labeling on plots shows antibody specificity. Anti-Id Ab preparations were selected for reaction with A31 or BCL1 Id Ig, as appropriate. Survival was recorded daily. Only cohorts treated with [huCD64 × Id] BsAb showed a significant increase in survival over all control groups (P < .02).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347003.jpeg?Expires=1725294245&Signature=QoDQyZJG2cm4aFICr4nm5aiunp3PizufVxR87PS3TGeQhOhacPUPCbu05EF3wHNLIs9sfKj~0XodyCl7Wr~xPmU1~Afa4K20ufWEXqO9ZOxyJmrld7BRMmNppihr433Hlsa-GPFVCEcS1gaoc-pKFeiUXyLybvFDe17wzE11WErS11qywirPYoXycpbZtMpxx2VdrbySbJ5vOZFLPegFTa1jqtuu6q-bEqdMRUsRgwvkf~-nEycYwnS2ld3LXvNINYAFyUNMH4~3Av1~w4c5Ttk9cxQ~OmkDTykxb9fXWWF5hZXBBEhcOwdZAs~XNTCyS5gZQNpxTrgfb-LkAIzv6w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Immunotherapy of A31- or BCL1-bearing mice with BsAb directed against huCD64 on the effector cells and Id on the tumors.
Groups of 5 huCD64+ age-matched mice received 2 μg/d murine G-CSF subcutaneously, 4 days before tumor inoculation, and throughout the course of therapy (10 days in total). Mice were inoculated with either 105 (BCL1) or 2 × 105 (A31) tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of 5 μg BsAb intraperitoneally on days 1 to 5 (50 μg/mouse in total). (This treatment schedule is shown in the inset.) Treatment was as indicated: PBS (●), anti-huCD64 F(ab')2 (⋄), anti-Id F(ab')2 (■), a mixture of anti-Id and anti-huCD64 F(ab')2 (♦), [huCD64 × Id] (○). Symbol labeling on plots shows antibody specificity. Anti-Id Ab preparations were selected for reaction with A31 or BCL1 Id Ig, as appropriate. Survival was recorded daily. Only cohorts treated with [huCD64 × Id] BsAb showed a significant increase in survival over all control groups (P < .02).
